Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Letters   |    
Improvement in Psychotic Symptoms and Social Functioning After Augmentation of Paliperidone With Clozapine in a Patient With Schizoaffective Disorder
Yi-Cheng Hou, MSc; Chien-Han Lai, M.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2014;26:E26. doi:10.1176/appi.neuropsych.13010010
View Author and Article Information

Department of Nutrition, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, ROC

Corresponding author: Chien-Han Lai, M.D. Department of Psychiatry, Cheng Hsin General Hospital, Taipei City, Taiwan, ROCe-mail address: stephenlai99@gmail.com

Copyright © 2014 by the American Psychiatric Association

An erratum to this article has been published | view the erratum


To the Editor: “Mrs. B,” who had significant depression symptoms and psychotic symptoms with significant exacerbations of self-care in the past 7 months, was diagnosed with schizoaffective disorder, depressed subtype, because of persistent psychotic symptoms even after response of her depression with mirtazapine 60 mg/day. She still had significant psychotic symptoms even after several kinds of antipsychotics, such as risperidone 8 mg/day, olanzapine 30 mg/day, and aripiprazole 30 mg/day during her 1-month hospitalization (Brief Psychiatric Rating Scale−18 items [BPRS−18] scores: 56, especially in items of uncooperativeness [6 points], hallucinatory behaviors [7 points], hostility [6 points] and suspiciousness [6 points]). Because of apparent treatment-resistance, the antipsychotic was switched to clozapine 200 mg/day gradually, with excessive salivation side effects. The responses of her psychotic symptoms still remained limited after using clozapine (BPRS−18 scores: 53). Her self-care, social, and occupational functioning also did not improve (Social and Occupational Function Assessment Scale [SOFA] score: 20].

Figures in this Article

First Page Preview

View Large
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).



Yang  LP:  Oral paliperidone: a review of its use in the management of schizoaffective disorder.  CNS Drugs 2011; 25:523–538
[CrossRef] | [PubMed]
Huang  MW;  Yang  TT;  Ten  PR  et al:  Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.  BMC Clin Pharmacol 2012; 12:1
[CrossRef] | [PubMed]
Gopal  S;  Berwaerts  J;  Nuamah  I  et al:  Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia.  Neuropsychiatr Dis Treat 2011; 7:93–101
[CrossRef] | [PubMed]
Yoon  KS;  Park  TW;  Yang  JC  et al:  Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers.  Hum Psychopharmacol 2012; 27:305–314
[CrossRef] | [PubMed]
Kim  SW;  Chung  YC;  Lee  YH  et al:  Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.  Int Clin Psychopharmacol 2012; 27:267–274
[CrossRef] | [PubMed]
Bishara  D;  Taylor  D:  Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy, and tolerability.  Drugs 2008; 68:2269–2292
[CrossRef] | [PubMed]
References Container

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 33.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 26.  >
DSM-5™ Clinical Cases > Chapter 2.  >
Topic Collections
Psychiatric News